ÀÚ°¡ Ç÷´ç ÃøÁ¤ ±â±â ½ÃÀå : ±âȸ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м®, ¿¹Ãø(2025-2034³â)
Self-Monitoring Blood Glucose Monitoring Devices Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
»óǰÄÚµå : 1822602
¸®¼­Ä¡»ç : Global Market Insights Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 132 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,850 £Ü 6,975,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,050 £Ü 8,701,000
PDF & Excel (Multi User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,350 £Ü 12,009,000
PDF & Excel (Enterprise User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Global Market Insights Inc.°¡ ¹ßÇàÇÑ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¼¼°èÀÇ ÀÚ°¡ Ç÷´ç ÃøÁ¤ ±â±â ½ÃÀåÀº 2024³â¿¡ 198¾ï ´Þ·¯·Î Æò°¡µÇ¾ú°í, CAGR 11.8%·Î 2025³â 216¾ï ´Þ·¯, 2034³â¿¡´Â 591¾ï ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

ÀÚ°¡ Ç÷´ç ÃøÁ¤ ±â±â Market-IMG1

ƯÈ÷ ½ÅÈï ½ÃÀå¿¡¼­ 1Çü ¹× 2Çü ´ç´¢º´ ȯÀÚÀÇ ¼¼°èÀûÀÎ ±ÞÁõÀº ¸ÅÀÏ Æ÷µµ´ç ÃßÀûÀ» À§ÇÑ Æí¸®ÇÏ°í ½Å·ÚÇÒ ¼ö ÀÖ´Â SMBG ÀåÄ¡¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÁÂ½Ä »ýȰ ½ºÅ¸ÀÏ, °Ç°­¿¡ ÇØ·Î¿î ½Ä»ýȰ, ºñ¸¸·üÀÇ »ó½ÂÀÌ ´ç´¢º´ ÀÌȯÀ²ÀÇ »ó½Â¿¡ ±â¿©Çϰí Àֱ⠶§¹®¿¡ ÀþÀºÃþÀ̳ª Æø³ÐÀº Ãþ¿¡¼­ ´ç´¢º´À¸·Î Áø´ÜµÇ´Â »ç¶÷ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¹üÀ§
½ÃÀÛ ¿¬µµ 2024³â
¿¹Ãø ¿¬µµ 2025-2034³â
½ÃÀå ±Ô¸ð 198¾ï ´Þ·¯
¿¹Ãø ±Ý¾× 591¾ï ´Þ·¯
CAGR 11.8%

¼Ò¸ðǰ ¼ö¿ä Áõ°¡

¼Ò¸ðǰ ºÎ¹®Àº 2024³â¿¡ ´«¿¡ ¶ç´Â Á¡À¯À²À» Â÷ÁöÇßÀ¸¸ç, °Ë»ç ½ºÆ®¸³, ¶õ¼Â ¹× Á¦¾î ¼Ö·ç¼ÇÀÌ °ßÀÎÇß½À´Ï´Ù. ÀÌ Ç°¸ñÀº ¸ÅÀÏ ¸ð´ÏÅ͸µ¿¡ ÇʼöÀûÀ̹ǷΠ¼ö¿ä´Â Ç×»ó ³ôÀ¸¸ç ½ÃÀåÀÇ ²ÙÁØÇÑ ¼ºÀåÀ» À̲ø°í ÀÖ½À´Ï´Ù. °Ë»ç ½ºÆ®¸³Àº ±³Ã¼ »çÀÌŬÀÌ ºó¹øÇϱ⠶§¹®¿¡ ¼Ò¸ðǰ ÆÇ¸ÅÀÇ ´ëºÎºÐÀ» Â÷ÁöÇÕ´Ï´Ù. ¼ÒºñÀÚ°¡ º¸´Ù Á¤È®ÇÏ°í Æí¸®ÇÑ °Ë»ç¸¦ Ãß±¸ÇÏ´Â µ¿¾È, °¢ ȸ»ç´Â º¸´Ù ÀûÀº ¾çÀÇ Ç÷¾× »ùÇ÷Π½Å¼ÓÇÑ °á°ú¸¦ ¾òÀ» ¼ö ÀÖ´Â ½ºÆ®¸³À» »ý»êÇϵµ·Ï ±â¼ú Çõ½ÅÀ» ÁøÇàÇϰí ÀÖ½À´Ï´Ù. ¼Ò¸ðǰ ºÎ¹®ÀÇ È®´ë´Â ȯÀÚÀÇ ¾îµåÈ÷¾î·±½º À¯Áö¿¡ ÇʼöÀûÀ̸ç, Àå±âÀûÀÎ °í°´ ·Î¿­Æ¼ È®º¸¸¦ ¸ñÇ¥·Î ÇÏ´Â ¾÷°è °¢»ç·ÎºÎÅÍ °è¼ÓÇØ¼­ ¾öû³­ ÅõÀÚ¸¦ ¸ðÀ¸°í ÀÖ½À´Ï´Ù.

2Çü ´ç´¢º´ÀÇ À¯º´·ü »ó½Â

2Çü ´ç´¢º´ ºÎ¹®Àº »ýȰ½À°ü°ú °ü·ÃµÈ ´ç´¢º´ ȯÀÚÀÇ ¼¼°è Áõ°¡¸¦ ¹Ý¿µÇÏ¿© 2024³â¿¡ Å« ¼öÀÍÀ» ¿Ã·È½À´Ï´Ù. 2Çü ´ç´¢º´ ȯÀÚ´Â Á¾Á¾ ´ÙÀÌ¾îÆ® ¹× ¾à¹° ¿ä¹ý°ú º´ÇàÇÏ¿© º´¸®ÇÐÀ» È¿°úÀûÀ¸·Î °ü¸®Çϱâ À§ÇØ Á¤±âÀûÀÎ Æ÷µµ´ç ¸ð´ÏÅ͸µÀÌ ÇÊ¿äÇÕ´Ï´Ù. ÀÌ ºÐ¾ß´Â Áúº´ °ü¸®¿¡ ´ëÇÑ ÀǽÄÀÌ Çâ»óµÇ°í °Ç°­ °ü¸® Á¦°ø¾÷ü°¡ ÇÕº´Áõ ¿¹¹æ¿¡¼­ Ç÷´ç Á¶ÀýÀÇ Á߿伺À» °­Á¶ÇÔ¿¡ µû¶ó ±Þ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. 2Çü ´ç´¢º´ ȯÀÚ¿¡°Ô SMBG ±â±â´Â ÇÕ¸®ÀûÀÎ °¡°ÝÀ¸·Î »ç¿ëÇϱ⠽±±â ¶§¹®¿¡ Çʼö µµ±¸ÀÔ´Ï´Ù.

Ȩ Äɾ °ßÀÎ ¿ªÇÒ¿¡

ÀçÅà ÄÉ¾î ºÐ¾ß´Â È¯ÀÚ Áß½ÉÀÇ ¿ø°Ý ÀÇ·á °ü¸® µ¿Çâ¿¡ °ßÀεǾî 2024³â¿¡ Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÆíÀǼº, ÇÁ¶óÀ̹ö½Ã, ¿ø°Ý ÀÇ·á ¼­ºñ½ºÀÇ Áö¼ÓÀûÀÎ È®´ë°¡ µ¿±â ºÎ¿©µÇ¾î Áý¿¡¼­ Æí¾ÈÇÏ°Ô Ç÷´çÀ» ¸ð´ÏÅ͸µÇÏ´Â °ÍÀ» ¼±È£ÇÏ´Â °³ÀÎÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ ºÎ¹®Àº ÀÇ·á Àü¹®°¡¿Í ½Ç½Ã°£ µ¥ÀÌÅÍ °øÀ¯¸¦ °¡´ÉÇÏ°Ô ÇÏ´Â ½º¸¶Æ®Æù Áö¿ø ÀåÄ¡ ¹× µðÁöÅÐ °Ç°­ Ç÷§Æû°ú °°Àº ±â¼úÀû Áøº¸ÀÇ ÇýÅÃÀ» ´©¸®°í ÀÖ½À´Ï´Ù. ÀçÅÃÄ¡·áÀÇ Ã¤ÅÃÀº ¶ÇÇÑ ÀÓ»ó Àå¼Ò ÀÌ¿ÜÀÇ ¸¸¼º Áúȯ °ü¸®¸¦ Á¡Á¡ ´õ Áß¿äÇÏ°Ô ¸¸µé°í ÀÖ½À´Ï´Ù.

Áö¿ªº° ÀλçÀÌÆ®

ºÏ¹Ì°¡ À¯¸ÁÇÑ Áö¿ªÀ¸·Î »ó½Â

ºÏ¹Ì ÀÚ°¡ Ç÷´ç ÃøÁ¤ ±â±â ½ÃÀåÀº 2024³â¿¡ ÁÖ¸ñÇÒ¸¸ÇÑ Á¡À¯À²À» ȹµæÇß½À´Ï´Ù. °­·ÂÇÑ ÇコÄɾî ÀÎÇÁ¶ó, ´ç´¢º´ ÀÌȯÀ²ÀÇ ³ôÀÌ, º¸Çè Àû¿ë ¹üÀ§ÀÇ ³ÐÀ̰¡ ÀÌ·¯ÇÑ ±â±âÀÇ ¿Õ¼ºÇÑ ¼ö¿ä¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀÇ ¼ÒºñÀÚµéÀº Á¤È®¼º, ÆíÀǼº, µðÁöÅÐ Çコ ¿¡ÄڽýºÅÛ°úÀÇ ÅëÇÕÀ» ¼±È£Çϰí ÀÖÀ¸¸ç, ÀÌ´Â Á¦Á¶¾÷üÀÇ ±Þ¼ÓÇÑ Çõ½ÅÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¾÷°è ¼±µµÀû ÀÎ Á¸Àç¿Í È®¸³ µÈ ±ÔÁ¦ ȯ°æÀº °íǰÁú Ç¥Áذú Á¦Ç°ÀÇ ½Å·Ú¼ºÀ» º¸ÀåÇÕ´Ï´Ù.

ÀÚ°¡ Ç÷´ç ÃøÁ¤ ±â±â ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº All Medicus, DarioHealth, B. Braun Melsungen, Ypsomed Holding, Sanofi, Bionime Corporation, AgaMatrix, Nova Biomedical, LifeScan, Arkray, Omnis Health, Sinocare, Abbott Laboratories, F. Hoffmann-La Roche, and Ascensia Diabetes Care HoldingsµîÀÌ ÀÖ½À´Ï´Ù.

½ÃÀå ±â¹ÝÀ» °­È­Çϱâ À§ÇØ ÀÚ°¡ Ç÷´ç ÃøÁ¤ ±â±â ½ÃÀåÀÇ °¢ ȸ»ç´Â Çõ½Å, ÆÄÆ®³Ê½Ê ¹× ȯÀÚ Âü¿©¿¡ ÁßÁ¡À» µÓ´Ï´Ù. Á¦Ç° °³¹ßÀº Á¤È®¼º, »ç¿ë ÆíÀǼº, ¿¬°á¼º¿¡ ÁßÁ¡À» µÎ°í ÀÖÀ¸¸ç, ¸¹Àº Á¦Á¶¾÷üµéÀÌ º¸´Ù ±¤¹üÀ§ÇÑ µðÁöÅÐ °Ç°­ Ç÷§Æû°ú ÅëÇÕÇÏ´Â ¾Û Áö¿ø ¹ÌÅ͸¦ Ãâ½ÃÇÕ´Ï´Ù. ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü ¹× º¸Çè ȸ»ç¿ÍÀÇ Àü·«Àû Á¦ÈÞ´Â »óȯ °èȹ ¹× ¹øµé °ü¸® ÇÁ·Î±×·¥À» ÅëÇØ ÀåÄ¡ÀÇ °¡¿ë¼ºÀ» È®´ëÇϰí ÀÖ½À´Ï´Ù. °¢ ȸ»ç´Â ¶ÇÇÑ Æ¯È÷ ½ÅÈï ½ÃÀå¿¡¼­ ȯÀÚÀÇ ¸®ÅÍ·¯½Ã¿Í Ãæ°í¸¦ Çâ»ó½Ã۱â À§ÇØ ±³À° ÀÌ´Ï¼ÅÆ¼ºê¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¾÷°è ÀλçÀÌÆ®

Á¦4Àå °æÀï ±¸µµ

Á¦5Àå ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø : Á¦Ç°º°, 2021-2034

Á¦6Àå ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø : ¿ëµµº°, 2021-2034

Á¦7Àå ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø : ÃÖÁ¾ ¿ëµµº°, 2021-2034

Á¦8Àå ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø : ±¹°¡º°, 2021-2034

Á¦9Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

SHW
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global self-monitoring blood glucose monitoring devices market was estimated at USD 19.8 billion in 2024 and is expected to grow from USD 21.6 billion in 2025 to USD 59.1 billion in 2034, at a CAGR of 11.8%, according to the latest report published by Global Market Insights Inc.

Self-Monitoring Blood Glucose Monitoring Devices Market - IMG1

The global surge in type 1 and type 2 diabetes cases, particularly in emerging markets, is driving demand for convenient and reliable SMBG devices for daily glucose tracking. As sedentary lifestyles, unhealthy diets, and rising obesity rates contribute to a higher incidence of diabetes, more individuals are being diagnosed at younger ages and across wider demographics.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$19.8 Billion
Forecast Value$59.1 Billion
CAGR11.8%

Rising Demand for Consumables

The consumables segment held a notable share in 2024, driven by test strips, lancets, and control solutions. As these items are essential for daily monitoring, their demand remains consistently high, driving steady market growth. Test strips dominate consumables sales due to their frequent replacement cycles. As consumers seek more accurate and convenient testing, companies are innovating to produce strips that require smaller blood samples and deliver faster results. The consumables segment's expansion is critical for maintaining patient adherence, and it continues to attract substantial investment from industry players aiming to secure long-term customer loyalty.

Rising Prevalence of Type 2 Diabetes

The type 2 diabetes segment generated significant revenues in 2024, reflecting the global rise in lifestyle-related diabetes cases. Patients with type 2 diabetes often require regular glucose monitoring to manage their condition effectively alongside diet and medication. This segment is growing rapidly as awareness about disease management improves and healthcare providers emphasize the importance of glycemic control in preventing complications. The affordability and ease of use of SMBG devices for type 2 diabetes patients make them indispensable tools.

Homecare to Gain Traction

The homecare segment held a significant share in 2024, driven by the trend toward patient-centered and remote healthcare management. More individuals prefer monitoring their blood glucose levels from the comfort of their homes, motivated by convenience, privacy, and the ongoing expansion of telehealth services. This segment benefits from technological advancements, including smartphone-compatible devices and digital health platforms that enable real-time data sharing with healthcare professionals. Homecare adoption also aligns with the increasing emphasis on chronic disease management outside clinical settings.

Regional Insights

North America to Emerge as a Lucrative Region

North America self-monitoring blood glucose monitoring devices market generated a notable share in 2024. Strong healthcare infrastructure, high diabetes prevalence, and widespread insurance coverage contribute to robust demand for these devices. Consumers in this region prioritize accuracy, convenience, and integration with digital health ecosystems, which has pushed manufacturers to innovate rapidly. Additionally, the presence of major industry players and a well-established regulatory environment ensures high-quality standards and product reliability.

Major players in the self-monitoring blood glucose monitoring devices market are All Medicus, DarioHealth, B. Braun Melsungen, Ypsomed Holding, Sanofi, Bionime Corporation, AgaMatrix, Nova Biomedical, LifeScan, Arkray, Omnis Health, Sinocare, Abbott Laboratories, F. Hoffmann-La Roche, and Ascensia Diabetes Care Holdings.

To strengthen their market foothold, companies in the self-monitoring blood glucose monitoring devices market are focusing heavily on innovation, partnerships, and patient engagement. Product development emphasizes accuracy, ease of use, and connectivity, with many manufacturers launching app-enabled meters that integrate with broader digital health platforms. Strategic collaborations with healthcare providers and insurance companies are expanding device accessibility through reimbursement schemes and bundled care programs. Companies are also investing in educational initiatives to improve patient literacy and adherence, especially in emerging markets.

Table of Contents

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

Chapter 3 Industry Insights

Chapter 4 Competitive Landscape, 2024

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

Chapter 8 Market Estimates and Forecast, By Country, 2021 - 2034 ($ Mn)

Chapter 9 Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â